Overall verdict
Buy
7.0/10
1-year performance
+36.13%
Score breakdown
Up 36.1% over 1 year, 75% of the 52-week range.
Strongest: Profitability 9.6/10. Weakest: Financial strength 5.4/10.
28 analysts, target +0.1% vs the price.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications ; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors ; Orencia for active rheumatoid arthritis and psoriatic arthritis ;
Yervoy for the treatment of unresectable or metastatic melanoma ; Reblozyl to treat anemia ; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma ; Opdualag to treat unresectable or metastatic melanoma ; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis ; Abecma for the treatment of patients with relapsed or refractory multiple myeloma ;
Sotyktu to treat moderate-to-severe plaque psoriasis ; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ; and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE ; Revlimid, an oral immunomodulatory drug for multiple myeloma ; Pomalyst/Imnovid for multiple myeloma ;
Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia ; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Christopher Boerner
Founded
1887
Employees
32 500
Revenue / employee
1.5M USD
Next earnings
October 29, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.8.95%
- VANGUARD CAPITAL MANAGEMENT LLC6.62%
- STATE STREET CORP5.08%
- JPMORGAN CHASE & CO3.56%
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC3.36%
- GEODE CAPITAL MANAGEMENT, LLC2.80%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.33%
- NORGES BANK1.83%
- BANK OF AMERICA CORP /DE/1.69%
- Other institutions46.62%
- Rest of the register17.16%
2511 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
68.64 USD
52-week low
42.52 USD
1-year performance
36.13%
Rising
Year-to-date performance
14.92%
Rising
Drawdown
-9.66%
Mild pullback
Position in the 52-week range
75% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 2.0 times harder.
10,000 € placed at the end of September 2009 are worth today
| Bristol-Myers Squibb | 67 295 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-51 % between November 2022 and July 2024. 10,000 € placed at the top fell to 4 889 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Bristol-Myers Squibb earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Bristol-Myers Squibb: 67 295 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 54.30 USD - 71.30 USD (2 methods agree)
The price implies growth of -2.99% per year; the company grows at 2.54%.
Gross margin 66.6%, net margin 18.9%, ROIC 14.3%, ROE 46.7%.
Net margin
18.87%
Exceptional
Sector 9.43%|S&P 12.97%
Gross margin
66.64%
High
Return on equity (ROE)
46.70%
Exceptional
Sector 6.16%|S&P 16.52%
Return on invested capital (ROIC)
14.32%
Exceptional
Free cash flow margin (FCF)
23.25%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.23x
High
Margin stability
14.9 pts
Very uneven
Revenue to net income
Growth
6.7/10Revenue up 5.8% over 1 year, 2.5% a year over 5.
Revenue (trailing 12 months)
49.2Md USD
Revenue growth (1y)
5.81%
Solid
Revenue growth (3y)
4.41%
Moderate
EPS growth (1y)
151.96%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
10.11%
Sharply revised up
Valuation
9.3/10P/E 13.7x, forward P/E 11.0x, EV/EBITDA 8.3x, PEG 0.16. The multiple sits in the 46th percentile of its own 5-year history.
P/E (TTM)
13.7x
Cheap
Sector 27.5x|S&P 23.0x
Forward P/E
11.0x
Fair
EV / EBITDA
8.3x
Cheap
Sector 16.1x|S&P 14.5x
PEG
0.16
Growth unpriced
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
64.74 USD
Fairly priced
P/E vs its own 5-year history
among the 46% lowest valuations
In line with its history
Market cap
125Md USD
Financial strength
5.4/10Cash covers 24.6% of the debt, net debt/EBITDA 1.9x.
Net debt / EBITDA
1.9x
Tight
Gearing (net debt / equity)
152.27%
Stretched
Cash
11.1Md USD
Cash / market cap
8.86%
Solid
Cash / total debt
24.56%
Tight
Net debt
34.0Md USD
Equity
22.3Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 61.50 USD
- MM2064.56
- MM5064.31
- MM20059.08
- RSI 1435.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.01%
200-day average slope, 3 months
+9.92%
50-day average slope, 1 month
+5.43%
Bullish RSI divergence
No
20-day volatility
1.01 % per day
Volatility change
-40.23%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.61 (9) | 6.95 (27) | 49 842 (24) | 19 160 (11) | 11 176 (7) |
| 2027 | 5.63 (9) | 6.56 (28) | 48 208 (25) | 18 429 (12) | 10 517 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.0 | 8.1 | 125Md USD | 13.7x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 36.1 % | ||
| 2 | LLY | 6.7 | 6.0 | 1.1T USD | 39.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 58.4 % | ||
| 3 | NOVO B | 6.6 | 7.4 | 170Md USD | 9.5x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -32.6 % | ||
| 4 | NOVN | 6.4 | 6.4 | 261Md USD | 22.6x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 22.0 % | ||
| 5 | JNJ | 6.3 | 5.9 | 649Md USD | 31.2x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.7 % | ||
| 6 | ROP | 6.1 | 5.7 | 352Md USD | 23.7x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 35.9 % | ||
| 7 | AZN | 5.8 | 6.5 | 255Md USD | 24.8x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.2 % | 10.7 % | ||
| 8 | MRK | 5.0 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 85.2 % | ||
| 9 | PFE | 4.9 | 4.6 | 161Md USD | 37.3x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 17.5 % |
